Report cover image

Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Toxicology Testing, Bioanalysis & DMPK Studies, Chemistry), By Model Type, By End-use, By Region, And Segment Forecasts, 2025 - 2033

Published Sep 01, 2025
Length 150 Pages
SKU # GV20470918

Description

Preclinical CRO Market Summary

The global preclinical CRO market size was estimated at USD 6.19 billion in 2024 and is projected to reach USD 12.37 billion by 2033, growing at a CAGR of 8.03% from 2025 to 2033. The market is driven escalating R&D investments, the growing complexity of drug development, and the shifting demand toward specialized and advanced therapeutic modalities.

The market is primarily driven by the increasing complexity of drug discovery, along with the high costs of in-house research infrastructure, is driving greater adoption of preclinical CRO services. Drug developers are outsourcing studies such as toxicology, pharmacology, and bioanalysis to specialized service providers to reduce time-to-market and manage operational risks. This trend is further amplified by the growing prevalence of chronic and complex diseases, which require more extensive preclinical evaluations. Outsourcing also enables smaller biotech firms, which often have limited resources, to access advanced technologies and global expertise without the need for large-scale internal setups.

Global Preclinical CRO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global preclinical CRO market report based on service, model type, end-use, and region:
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Bioanalysis and DMPK studies
  • In vitro ADME
  • In-vivo PK
  • Toxicology Testing
  • GLP
  • Non-GLP
  • Compound Management
  • Process R&D
  • Custom Synthesis
  • Others
  • Chemistry
  • Medicinal Chemistry
  • Computation Chemistry
  • Safety Pharmacology
  • Others
  • Model Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Patient Derived Organoid (PDO) Model
  • Patient derived xenograft model
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Biopharmaceutical Companies
  • Government and Academic Institutes
  • Medical Device Companies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Norway
  • Sweden
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

150 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value chain based analysis (Model 2)
1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Preclinical CRO Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Preclinical CRO Market Dynamics
3.2.1. Market Driver Impact Analysis
3.2.2. Market Restraint Analysis
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Preclinical CRO Market: Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
Chapter 4. Preclinical CRO Market: Service Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Preclinical CRO Market Service Movement Analysis
4.3. Global Preclinical CRO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
4.4. Bioanalysis and DMPK Studies
4.4.1. Bioanalysis and DMPK Studies Market Estimates and Forecasts, 2021 - 2033 (USD million)
4.4.2. In vitro ADME
4.4.2.1. In vitro ADME Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3. In-vivo PK
4.4.3.1. In-vivo PK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Toxicology Testing
4.5.1. Toxicology Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.2. GLP
4.5.2.1. GLP Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.3. Non-GLP
4.5.3.1. Non-GLP Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Compound Management
4.6.1. Compound Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.2. Process R&D
4.6.2.1. Process R&D Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.3. Custom Synthesis
4.6.3.1. Custom Synthesis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.4. Others
4.6.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Chemistry
4.7.1. Chemistry Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7.2. Medicinal Chemistry
4.7.2.1. Medicinal Chemistry Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7.3. Computation Chemistry
4.7.3.1. Computation Chemistry Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Safety Pharmacology
4.8.1. Safety Pharmacology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.9. Others
4.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Preclinical CRO Market: Model Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Preclinical CRO Market Model type Movement Analysis
5.3. Global Preclinical CRO Market Size & Trend Analysis, by Model type, 2021 to 2033 (USD Million)
5.4. Patient Derived Organoid (PDOs) Models
5.4.1. Patient Derived Organoid (PDOs) Models Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Patient Derived Xenograft (PDX) Models
5.5.1. Patient Derived Xenograft (PDX) Models Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Preclinical CRO Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Preclinical CRO Market End Use Movement Analysis
6.3. Global Preclinical CRO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Biopharmaceutical Companies
6.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Government and Academic Institutes
6.5.1. Government and Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Medical Device Companies
6.6.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Preclinical CRO Market: Regional Estimates & Trend Analysis by Service, Model Type, End Use
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Europe
7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Framework
7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Framework
7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Framework
7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Framework
7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Competitive Scenario
7.5.9.3. Regulatory Framework
7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Framework
7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Latin America
7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. MEA
7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Framework
7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.6. Oman
7.8.6.1. Key Country Dynamics
7.8.6.2. Competitive Scenario
7.8.6.3. Regulatory Framework
7.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.7. Qatar
7.8.7.1. Key Country Dynamics
7.8.7.2. Competitive Scenario
7.8.7.3. Regulatory Framework
7.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Preclinical CRO Market Share Analysis, 2024
8.3. Company Profiles
8.3.1. Eurofins Scientific
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Product benchmarking
8.3.1.4. Strategic initiatives
8.3.2. PRA Health Sciences, Inc.
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Wuxi AppTec
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Medpace, Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Charles River Laboratories International, Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. PPD Thermo Fisher Scientific, Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. SGA SA
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Intertek Group Plc (IGP)
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. LABCORP
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Crown Bioscience
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.